Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850168 | 0.81 | LMNA (0.61) | TAS2R14LMNAKCNA5TP53POLB | |
| SCHEMBL3859021 | 0.81 | TAS2R14 (0.50) | TAS2R14LMNAKCNA5TP53POLB | |
| SCHEMBL3851675 | 0.79 | TAS2R14 (0.51) | TAS2R14LMNAKCNA5 | |
| SCHEMBL3859027 | 0.78 | TAS2R14 (0.52) | TAS2R14LMNAHTTTP53POLB | |
| SCHEMBL3858004 | 0.76 | TAS2R14 (0.49) | TAS2R14LMNAKCNA5MAPK1 | |
| SCHEMBL3858712 | 0.76 | TAS2R14 (0.49) | TAS2R14LMNAKCNA5TP53MAPK1 | |
| SCHEMBL3851680 | 0.75 | TAS2R14 (0.74) | TAS2R14KCNA5 | |
| SCHEMBL3852814 | 0.74 | TAS2R14 (0.54) | TAS2R14LMNAPOLBMAPK1 | |
| SCHEMBL3848953 | 0.72 | CNR2 (0.62) | TAS2R14LMNAMAPK1 | |
| SCHEMBL3857290 | 0.71 | TAS2R14 (0.53) | TAS2R14LMNAHTTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | TAS2R14 4736/4885LMNA 830/4885HTT 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.